Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms

  • Vázquez Borrego, María del Carmen
  • Fuentes-Fayos, Antonio C.
  • Herrera-Martínez, Aura D.
  • L-López, Fernando
  • Ibáñez-Costa, Alejandro
  • Moreno Moreno, Paloma
  • Alhambra Expósito, María Rosa
  • Barrera-Martín, Ana
  • Blanco-Acevedo, Cristóbal
  • Dios, Elena
  • Venegas-Moreno, Eva
  • Solivera, Juan
  • Gahete Ortiz, Manuel D.
  • Soto-Moreno, Alfonso
  • Gálvez-Moreno, M. Ángeles
  • Castaño, Justo P.
  • Luque, Raúl M.
Context: Pituitary neuroendocrine tumors (PitNETs) are a commonly underestimated pathology in terms of incidence and associated morbimortality. Currently, an appreciable subset of patients are resistant or poorly responsive to the main current medical treatments [i.e., synthetic somatostatin analogs (SSAs) and dopamine agonists]. Thus, development and optimization of novel and available medical therapies is necessary. Biguanides (metformin, buformin, and phenformin) are antidiabetic drugs that exert antitumoral actions in several tumor types, but their pharmacological effects on PitNETs are poorly known. Objective: We aimed to explore the direct effects of biguanides on key functions (cell viability, hormone release, apoptosis, and signaling pathways) in primary cell cultures from human PitNETs and cell lines. Additionally, we evaluated the effect of combined metformin with SSAs on cell viability and hormone secretion. Design: A total of 13 corticotropinomas, 13 somatotropinomas, 13 nonfunctioning PitNETs, 3 prolactinomas, and 2 tumoral pituitary cell lines (AtT-20 and GH3) were used to evaluate the direct effects of biguanides on cell viability, hormone release, apoptosis, and signaling pathways. Results: Biguanides reduced cell viability in all PitNETs and cell lines (with phenformin being the most effective biguanide) and increased apoptosis in somatotropinomas. Moreover, buformin and phenformin, but not metformin, reduced hormone secretion in a cell type–specific manner. Combination metformin/SSA therapy did not increase SSA monotherapy effectiveness. Effects of biguanides on PitNETs could involve the modulation of AMP-activated protein kinase–dependent ([Ca21]i, PI3K/Akt) and independent (MAPK) mechanisms. Conclusion: Altogether, our data unveil clear antitumoral effects of biguanides on PitNET cells, opening avenues to explore their potential as drugs to treat these pathologies. (J Clin Endocrinol Metab 104: 3501–3513, 2019)
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly

  • Venegas-Moreno, Eva
  • Vázquez Borrego, María del Carmen
  • Dios, Elena
  • Gros-Herguido, Noelia
  • Flores Martínez, Álvaro
  • Rivero-Cortés, Esther
  • Madrazo Atutxa, Ainara M.
  • Japón, Miguel Ángel
  • Luque, Raúl M.
  • Castaño, Justo P.
  • Cano, David A.
  • Soto-Moreno, Alfonso
Acromegaly is a hormonal disorder resulting from excessive growth hormone (GH) secretion frequently produced by pituitary adenomas and consequent increase in insulin-like growth factor 1 (IGF-I). Elevated GH and IGF-I levels result in a wide range of somatic, cardiovascular, endocrine, metabolic and gastrointestinal morbidities. Somatostatin analogues (SSAs) form the basis of medical therapy for acromegaly and are currently used as first-line treatment or as second-line therapy in patients undergoing unsuccessful surgery. However, a considerable percentage of patients do not respond to SSAs treatment. Somatostatin receptors (SSTR1-5) and dopamine receptors (DRD1-5) subtypes play critical roles in the regulation of hormone secretion. These receptors are considered important pharmacological targets to inhibit hormone oversecretion. It has been proposed that decreased expression of SSTRs may be associated with poor response to SSAs. Here, we systematically examine SSTRs and DRDs expression in human somatotroph adenomas by quantitative PCR. We observed an association between the response to SSAs treatment and DRD4, DRD5, SSTR1 and SSTR2 expression. We also examined SSTR expression by immunohistochemistry and found that the immunohistochemical detection of SSTR2 in particular might be a good predictor of response to SSAs.
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Association between radiological parameters and clinical and molecular characteristics in human somatotropinomas

  • Alhambra Expósito, María Rosa
  • Ibáñez-Costa, Alejandro
  • Moreno Moreno, Paloma
  • Rivero-Cortés, Esther
  • Vázquez Borrego, María del Carmen
  • Blanco-Acevedo, Cristóbal
  • Toledano-Delgado, Álvaro
  • Lombardo Galera, María Sagrario
  • Vallejo-Casas, Juan-Antonio
  • Gahete Ortiz, Manuel D.
  • Castaño, Justo P.
  • Gálvez-Moreno, M. Ángeles
  • Luque, Raúl M.
Acromegaly is a rare but severe disease, originated in 95% of cases by a growth hormone-secreting adenoma (somatotropinoma) in the pituitary. Magnetic resonance imaging (MRI) is a non-invasive technique used for the diagnosis and prognosis of pituitary tumours. The aim of this study was to determine whether the use of T2-weighted signal intensity at MRI could help to improve the characterisation of somatotropinomas, by analysing its relationship with clinical/molecular features. An observational study was implemented in a cohort of 22 patients (mean age = 42.1 ± 17.2 years; 59% women; 95% size>10 mm). Suprasellar-extended somatotropinomas presented larger diameters vs. non-extended tumours. T2-imaging revealed that 59% of tumours were hyperintense and 41% isointense adenomas, wherein hyperintense were more invasive (according to Knosp-score) than isointense adenomas. A higher proportion of hyperintense somatotropinomas presented extrasellar-growth, suprasellar-growth and invasion of the cavernous sinus compared to isointense adenomas. Interestingly, somatostatin receptor-3 and dopamine receptor-5 (DRD5) expression levels were associated with extrasellar and/or suprasellar extension. Additionally, DRD5 was also higher in hyperintense adenomas and its expression was directly correlated with Knosp-score and with tumour diameter. Hence, T2-weighted MRI on somatotropinomas represents a potential tool to refine their diagnosis and prognosis, and could support the election of preoperative treatment, when required.
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells

  • Vázquez Borrego, María del Carmen
  • L-López, Fernando
  • Gálvez-Moreno, M. Ángeles
  • Fuentes-Fayos, Antonio C.
  • Venegas-Moreno, Eva
  • Herrera-Martínez, Aura D.
  • Blanco-Acevedo, Cristóbal
  • Solivera, Juan
  • Landsman, Tanya
  • Gahete Ortiz, Manuel D.
  • Soto-Moreno, Alfonso
  • Culler, Michael D.
  • Castaño, Justo P.
  • Luque, Raúl M.
Background: Pituitary neuroendocrine tumors (PitNETs) represent approximately 15% of all intracranial tumors and usually are associated with severe comorbidities. Unfortunately, a relevant number of patients do not respond to currently available pharmacological treatments, that is, somatostatin analogs (SSAs) or dopamine-agonists (DA). Thus, novel, chimeric somatostatin/dopamine compounds (dopastatins) that could improve medical treatment of PitNETs have been designed. Objective: This study aims to determine the direct therapeutic effects of a new-generation dopastatin, BIM-065, on primary cell cultures from different PitNETs subtypes. Methods: Thirty-one PitNET-derived cell cultures (9 corticotropinomas, 9 somatotropinomas, 11 nonfunctioning pituitary adenomas [NFPAs], and 2 prolactinomas), were treated with BIM-065, and key functional endpoints were assessed (cell viability, apoptosis, hormone secretion, expression levels of key genes, free cytosolic [Ca2+]i dynamics, etc.). AtT-20 cell line was used to evaluate signaling pathways in response to BIM-065. Results: This chimeric compound decreased cell viability in all corticotropinomas and somatotropinomas tested, but not in NFPAs. BIM-065 reduced ACTH, GH, chromogranin-A and PRL secretion, and increased apoptosis in corticotropinomas, somatotropinomas, and NFPAs. These effects were possibly mediated through modulation of pivotal signaling cascades like [Ca2+]i kinetic and Akt- or ERK1/2-phosphorylation. Conclusions: Our results unveil a robust antitumoral effect in vitro of the novel chimeric compound BIM-065 on the main PitNET subtypes, inform on the mechanisms involved, and suggest that BIM-065 could be an efficacious therapeutic option to be considered in the treatment of PitNETs.
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Statins Directly Regulate Pituitary Cell Function and Exert Antitumor Effects in Pituitary Tumors

  • Vázquez Borrego, María del Carmen
  • Fuentes-Fayos, Antonio C.
  • Herrera-Martínez, Aura D.
  • Venegas-Moreno, Eva
  • L-López, Fernando
  • Fanciulli, Alessandro
  • Moreno Moreno, Paloma
  • Alhambra Expósito, María Rosa
  • Barrera-Martín, Ana
  • Dios, Elena
  • Blanco-Acevedo, Cristóbal
  • Solivera, Juan
  • Granata, Riccarda
  • Kineman, Rhonda D
  • Gahete Ortiz, Manuel D.
  • Soto-Moreno, Alfonso
  • Gálvez-Moreno, M. Ángeles
  • Castaño, Justo P.
  • Luque, Raúl M.
Introduction: Pituitary neuroendocrine tumors (PitNETs), the most abundant of all intracranial tumors, entail severe comorbidities. First-line therapy is transsphenoidal surgery, but subsequent pharmacological therapy is often required. Unfortunately, many patients are/become unresponsive to available drugs (somatostatin analogues [SSAs]/dopamine agonists), underscoring the need for new therapies. Statins are well-known drugs commonly prescribed to treat hyperlipidemia/cardiovascular diseases, but can convey additional beneficial effects, including antitumor actions. The direct effects of statins on normal human pituitary or PitNETs are poorly known. Thus, we aimed to explore the direct effects of statins, especially simvastatin, on key functional parameters in normal and tumoral pituitary cells, and to evaluate the combined effects of simvastatin with metformin (MF) or SSAs. Methods: Effects of statins in cell proliferation/viability, hormone secretion, and signaling pathways were evaluated in normal pituitary cells from a primate model (Papio anubis), tumor cells from corticotropinomas, somatotropinomas, nonfunctioning pituitary tumors, and PitNET cell-lines (AtT20/GH3-cells). Results: All statins decreased AtT20-cell proliferation, simvastatin showing stronger effects. Indeed, simvastatin reduced cell viability and/or hormone secretion in all PitNETs subtypes and cell-lines, and ACTH/GH/PRL/FSH/LH secretion (but not expression), in primate cell cultures, by modulating MAPK/PI3K/mTOR pathways and expression of key receptors (GH-releasing hormone-receptor/ghrelin-R/Kiss1-R) regulating pituitary function. Addition of MF or SSAs did not enhance simvastatin antitumor effects. Conclusion: Our data reveal direct antitumor effects of simvastatin on PitNET-cells, paving the way to explore these compounds as a possible tool to treat PitNETs.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines

  • Rincón-Fernández, David
  • Culler, Michael D.
  • Tsomaia, Natia
  • Moreno-Bueno, Gema
  • Luque, Raúl M.
  • Gahete, Manuel D.
  • Castaño, Justo P.
Ghrelin gene generates several variants that regulate multiple pathophysiological functions, including tumor-related processes. In1-ghrelin is a splicing variant that was previously shown to be overexpressed in breast cancer (BCa), where it correlated with proliferation markers; however, its possible association with clinical outcome of BCa patients and underlying mechanisms are still unknown. To address this issue, expression levels and clinical associations of In1-ghrelin were analyzed in a cohort of 117 BCa samples. Additionally, a battery of cellular and molecular assays was implemented using two BCa cell lines (MCF-7 and MDA-MB-231), wherein the role of In1-ghrelin on proliferation, migration, dedifferentiation and signaling pathways was explored. The results generated revealed that high expression of In1-ghrelin in BCa samples was associated with lymph node metastasis and reduced disease-free survival. Indeed, In1-ghrelin overexpression stimulated proliferation and migration in MCF-7 and MDA-MB-231 cells. Similar results were found by treating MDA-MB-231 and MCF-7 with In1-ghrelin-derived peptides. Conversely, In1-ghrelin silencing decreased proliferation and migration capacities of MDA-MB-231. Furthermore, In1-ghrelin (but not ghrelin) overexpression increased the capacity to form mammospheres in both cell lines. These effects could be associated with activation of MAPK-ERK, Jag1/Notch, Wnt/β-catenin and/or TGF-β1 pathways. Altogether, our data indicate that In1-ghrelin could play relevant functional roles in the regulation of BCa development and progression and may provide insights to identify novel biomarkers and new therapeutic approaches for this pathology., BIO-0139, CTS-1406, PI-639–2012, PI-0541-2013 (Junta de Andalucia), BFU2013-43282-R, BFU2016-80360-R (MINECO), PI16/00264, CP15/00156 and “Miguel Servet” Program [Proyectos de Investigación en Salud FIS, funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future”)], and CIBERobn (to RML, MDG and JPC); PI16/00134 [Proyectos de Investigación en Salud FIS, funded by Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, “Investing in your future”)] and CB16/12/00295 (CIBERONC) (to GMB). CIBER is an initiative of Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain. Tissue samples were obtained with the support of MD Anderson Foundation Biobank (record number B.0000745, ISCIII National Biobank Record)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Biguanides Exert Antitumoral Actions in Pituitary Tumor Cells Through AMPK-Dependent and -Independent Mechanisms

  • Vázquez-Borrego, Mari C.
  • Fuentes-Fayos, Antonio C.
  • Herrera-Martínez, Aura D.
  • López, Fernando L.
  • Ibáñez-Costa, Alejandro
  • Moreno-Moreno, Paloma
  • Alhambra-Expósito, María R.
  • Barrera-Martín, Ana
  • Blanco-Acevedo, Cristóbal
  • Dios Fuentes, Elena
  • Venegas Moreno, Eva
  • Solivera, Juan
  • Gahete, Manuel D.
  • Soto-Moreno, Alfonso
  • Gálvez-Moreno, María Ángeles
  • Castaño, Justo P.
  • Luque, Raúl M.
[Context] Pituitary neuroendocrine tumors (PitNETs) are a commonly underestimated pathology in terms of incidence and associated morbimortality. Currently, an appreciable subset of patients are resistant or poorly responsive to the main current medical treatments [i.e., synthetic somatostatin analogs (SSAs) and dopamine agonists]. Thus, development and optimization of novel and available medical therapies is necessary. Biguanides (metformin, buformin, and phenformin) are antidiabetic drugs that exert antitumoral actions in several tumor types, but their pharmacological effects on PitNETs are poorly known., [Objective] We aimed to explore the direct effects of biguanides on key functions (cell viability, hormone release, apoptosis, and signaling pathways) in primary cell cultures from human PitNETs and cell lines. Additionally, we evaluated the effect of combined metformin with SSAs on cell viability and hormone secretion., [Design] A total of 13 corticotropinomas, 13 somatotropinomas, 13 nonfunctioning PitNETs, 3 prolactinomas, and 2 tumoral pituitary cell lines (AtT-20 and GH3) were used to evaluate the direct effects of biguanides on cell viability, hormone release, apoptosis, and signaling pathways., [Results] Biguanides reduced cell viability in all PitNETs and cell lines (with phenformin being the most effective biguanide) and increased apoptosis in somatotropinomas. Moreover, buformin and phenformin, but not metformin, reduced hormone secretion in a cell type–specific manner. Combination metformin/SSA therapy did not increase SSA monotherapy effectiveness. Effects of biguanides on PitNETs could involve the modulation of AMP-activated protein kinase–dependent ([Ca2+]i, PI3K/Akt) and independent (MAPK) mechanisms., [Conclusion] Altogether, our data unveil clear antitumoral effects of biguanides on PitNET cells, opening avenues to explore their potential as drugs to treat these pathologies., This work has been funded by the following grants: Junta de Andalucía (CTS-1406 to R.M.L., BIO-0139 to J.P.C.), Ministerio de Ciencia, Innovación y Universidades (BFU2016-80360-R to J.P.C., FJCI-2016-30825 to A.I.C.), and Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF, “Investing in Your Future”: PI16/00264 to R.M.L., CP15/00156 to M.D.G., and CIBERobn). CIBER is an initiative of Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Development of Ependymal and Postnatal Neural Stem Cells and Their Origin from a Common Embryonic Progenitor

  • Redmond, Stephanie A.
  • Figueres-Oñate, Maria
  • Obernier, Kirsten
  • Assis Nascimento, Marcos
  • Parraguez, José I.
  • López-Mascaraque, Laura
  • Fuentealba, Luis C.
  • Alvarez-Buylla, A.
The adult mouse brain contains an extensive neuro-genic niche in the lateral walls of the lateral ventricles.This epithelium, which has a unique pinwheel organi-zation, contains multiciliated ependymal (E1) cellsand neural stem cells (B1). This postnatal germinalepithelium develops from the embryonic ventricularzone, but the lineage relationship between E1 andB1 cells remains unknown. Distinct subpopulationsof radial glia (RG) cells in late embryonic and earlypostnatal development either expand their apicaldomain >11-fold to form E1 cells or retain small api-cal domains that coalesce into the centers of pin-wheels to form B1 cells. Using independent methodsof lineage tracing, we show that individual RG cellscan give rise to clones containing E1 and B1 cells.This study reveals key developmental steps in theformation of the postnatal germinal niche and theshared cellular origin of E1 and B1 cells., The authors would like to thank members of the Alvarez-Buylla laboratory forhelpful discussions, William Walantus for technical expertise, and KennethXavier Probst of Xavier Studio for cell illustration designs. This study was sup-ported by funding from the Howard Hughes Medical Institute/Helen Hay Whit-ney Foundation (to L.C.F.); Becas Chile, Ministerio de Educación (to J.I.P.); Deutsche Forschungsgemeinschaft (to K.O.); NIH grant F32 NS103221 (toS.A.R.); MINECO (BFU2016-80360-R; to M.F.-O.); and NIH grants R37HD32116 and R01 NS28478, the Heather and Melanie Muss Endowed Chair,and a generous gift from the John G. Bowes Research Fund (to A.A.-B.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A New Generation Somatostatin-Dopamine Analogue Exerts Potent Antitumoral Actions on Pituitary Neuroendocrine Tumor Cells

  • Vázquez-Borrego, Mari C.
  • López, Fernando L.
  • Gálvez-Moreno, María Ángeles
  • Fuentes-Fayos, Antonio C.
  • Herrera-Martínez, Aura D.
  • Blanco-Acevedo, Cristóbal
  • Solivera, Juan
  • Landsman, T.
  • Gahete, Manuel D.
  • Soto-Moreno, Alfonso
  • Culler, Michael D.
  • Castaño, Justo P.
  • Luque, Raúl M.
[Background] Pituitary neuroendocrine tumors (PitNETs) represent approximately 15% of all intracranial tumors and usually are associated with severe comorbidities. Unfortunately, a relevant number of patients do not respond to currently available pharmacological treatments, that is, somatostatin analogs (SSAs) or dopamine-agonists (DA). Thus, novel, chimeric somatostatin/dopamine compounds (dopastatins) that could improve medical treatment of PitNETs have been designed. [Objective] This study aims to determine the direct therapeutic effects of a new-generation dopastatin, BIM-065, on primary cell cultures from different PitNETs subtypes., [Methods] Thirty-one PitNET-derived cell cultures (9 corticotropinomas, 9 somatotropinomas, 11 nonfunctioning pituitary adenomas [NFPAs], and 2 prolactinomas), were treated with BIM-065, and key functional endpoints were assessed (cell viability, apoptosis, hormone secretion, expression levels of key genes, free cytosolic [Ca2+]i dynamics, etc.). AtT-20 cell line was used to evaluate signaling pathways in response to BIM-065., [Results] This chimeric compound decreased cell viability in all corticotropinomas and somatotropinomas tested, but not in NFPAs. BIM-065 reduced ACTH, GH, chromogranin-A and PRL secretion, and increased apoptosis in corticotropinomas, somatotropinomas, and NFPAs. These effects were possibly mediated through modulation of pivotal signaling cascades like [Ca2+]i kinetic and Akt- or ERK1/2-phosphorylation., [Conclusions] Our results unveil a robust antitumoral effect in vitro of the novel chimeric compound BIM-065 on the main PitNET subtypes, inform on the mechanisms involved, and suggest that BIM-065 could be an efficacious therapeutic option to be considered in the treatment of PitNETs., This work was supported by the following grants: Junta de Andalucía (CTS-1406, BIO-0139); Instituto de Salud Carlos III-FIS (co-funded by European Union [ERDF/ESF, “Investing in your future”; PI16/00264, and “Miguel Servet” Program CP15/00156]), Ministerio de Ciencia, Innovación y Universidades, (BFU2016-80360-R) and CIBERobn. Ciber is an initiative of Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades, Spain.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma

  • González-Borja, Iranzu
  • Alors-Pérez, Emilia
  • Amat, Irene
  • Alonso, Laura
  • Viyuela-García, Cristina
  • Goñi, Saioa
  • Reyes, José C.
  • Ceballos-Chávez, María
  • Hernández-García, Irene
  • Sánchez-Frías, Marina E.
  • Santamaría, Enrique
  • Razquin, Socorro
  • Arjona-Sánchez, Álvaro
  • Arrazubi, Virginia
  • Pérez-Sanz, Jairo
  • Vera, Ruth
  • Fernández-Irigoyen, Joaquín
  • Castaño, Justo P.
  • Viudez, Antonio
Checkpoint with forkhead-associated and ring finger domains (CHFR) has been proposed as a predictive and prognosis biomarker for different tumor types, but its role in pancreatic ductal adenocarcinoma (PDAC) remains unknown. The aim of this study was two-pronged: to review the role of CHFR in PDAC and evaluating CHFR as a potential predictive biomarker in this disease. For this purpose, we first explored the CHFR messenger (m)RNA expression and promoter methylation through the TCGA database. Secondly, the CHFR expression and promoter methylation were prospectively evaluated in a cohort of patients diagnosed with borderline (n = 19) or resectable (n = 16) PDAC by immunohistochemistry (IHC), methylation specific-PCR (MSP), and pyrosequencing. The results from the TCGA database showed significant differences in terms of progression-free survival (PFS) and overall survival (OS) based on the CHFR mRNA expression, which was likely independent from the promoter methylation. Importantly, our results showed that in primarily resected patients and also the entire cohort, a higher CHFR expression as indicated by the higher IHC staining intensity might identify patients with longer disease-free survival (DFS) and OS, respectively. Similarly, in the same cohorts, patients with lower methylation levels by pyrosequencing showed significantly longer OS than patients without this pattern. Both, the CHFR expression intensity and its promoter methylation were established as independent prognostic factors for PFS and OS in the entire cohort. In contrast, no significant differences were found between different methylation patterns for CHFR and the response to taxane-based neoadjuvant treatment. These results suggest the potential role of the higher expression of CHFR and the methylation pattern of its promoter as potential prognostic biomarkers in PDAC, thus warranting further comprehensive studies to extend and confirm our preliminary findings., This work was funded by grants from the Department of Health from the Government of Navarra (Ref. 008-2018), REFBIO II Pyrenees Biomedical Network from Programa INTERREG V-A España-Francia-Andorra (Ref. BMK_PANC) and Sociedad Española de Oncología Médica (SEOM) to AV. IG-B was supported by a predoctoral fellowship from the Department of Economic Development Government of Navarre Ayudas para la contratación de doctorandos y doctorandas por empresas y organismos de investigación y difusión de conocimientos: doctorados industriales 2018–2020. Intensification Programme Navarrabiomed 2017-2021 Obra Social La Caixa Fundación Caja Navarra. This work has also been supported by the Spanish Ministry of Economy [MINECO; BFU2016-80360-R (to JC)] and the Ministry of Science and Innovation [MICINN; PID2019- 105201RB-I00 (to JC)]. Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF, Investing in your future) [Predoctoral contract FI17/00282 (to EA-P)]. Junta de Andalucía (BIO-0139); GETNE2016 and GETNE2019 Research grants (to JC); and CIBERobn.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Epigenetic and post-transcriptional regulation of somatostatin receptor subtype 5 (SST5 ) in pituitary and pancreatic neuroendocrine tumors

  • Pedraza-Arévalo, Sergio
  • Ibáñez-Costa, Alejandro
  • Blázquez-Encinas, Ricardo
  • Branco, Miguel R.
  • Vázquez-Borrego, Mari C.
  • Herrera-Martínez, Aura D.
  • Venegas Moreno, Eva
  • Serrano-Blanch, Raquel
  • Arjona-Sánchez, Álvaro
  • Gálvez-Moreno, María Ángeles
  • Korbonits, Marta
  • Soto-Moreno, Alfonso
  • Gahete, Manuel D.
  • Charalambous, Marika
  • Luque, Raúl M.
  • Castaño, Justo P.
Somatostatin receptor subtype 5 (SST5 ) is an emerging biomarker and actionable target in pituitary (PitNETs) and pancreatic (PanNETs) neuroendocrine tumors. Transcriptional and epigenetic regulation of SSTR5 gene expression and mRNA biogenesis is poorly understood. Recently, an overlapping natural antisense transcript, SSTR5-AS1, potentially regulating SSTR5 expression, was identified. We aimed to elucidate whether epigenetic processes contribute to the regulation of SSTR5 expression in PitNETs (somatotropinomas) and PanNETs. We analyzed the SSTR5/SSTR5-AS1 human locus in silico to identify CpG islands. SSTR5 and SSTR5-AS1 expression was assessed by quantitative real-time PCR (qPCR) in 27 somatotropinomas, 11 normal pituitaries (NPs), and 15 PanNETs/paired adjacent (control) samples. We evaluated methylation grade in four CpG islands in the SSTR5/SSTR5-AS1 genes. Results revealed that SSTR5 and SSTR5-AS1 were directly correlated in NP, somatotropinoma, and PanNET samples. Interestingly, selected CpG islands were differentially methylated in somatotropinomas compared with NPs. In PanNETs cell lines, SSTR5-AS1 silencing downregulated SSTR5 expression, altered aggressiveness features, and influenced pasireotide response. These results provide evidence that SSTR5 expression in PitNETs and PanNETs can be epigenetically regulated by the SSTR5-AS1 antisense transcript and, indirectly, by DNA methylation, which may thereby impact tumor behavior and treatment response., This research was funded by Junta de Andalucía (BIO-0139, P20_00442; PEER-0048-2020); Spanish Ministry of Economy (BFU2016-80360-R), Ministry of Science and Innovation (PID2019-105201RB-I00, PID2019-105564RB-I00); and ISCIII (PI16-00264, CD19/00255), co-funded with EU funds from FEDER Program. People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (FP7/2007-2013) under project WHRI-ACADEMY, REA grant agreement n° 608765; MECD (FPU14/04290, FPU18/02275); EMBO (short term fellowship 6802); GETNE G2019 Research Grant; Fundación Eugenio Rodriguez Pascual (FERP2019); project grants from the UK Medical Research Council (MR/R022836/1; MR/L002345/1); and CIBERobn; CIBER Fisiopatología de la Obesidad y Nutriciín is an initiative of Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Splicing alterations in pancreatic ductal adenocarcinoma: a new molecular landscape with translational potential

  • Alors-Perez, Emilia
  • Pedraza-Arévalo, Sergio
  • Blázquez-Encinas, Ricardo
  • Moreno-Montilla, María Trinidad
  • García-Vioque, Víctor
  • Berbel, Inmaculada
  • Luque, Raúl M.
  • Sainz, Bruno Jr.
  • Ibáñez-Costa, Alejandro
  • Castaño, Justo P.
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal cancers worldwide, mainly due to its late diagnosis and lack of effective therapies, translating into a low 5-year 12% survival rate, despite extensive clinical efforts to improve outcomes. International cooperative studies have provided informative multiomic landscapes of PDAC, but translation of these discoveries into clinical advances are lagging. Likewise, early diagnosis biomarkers and new therapeutic tools are sorely needed to tackle this cancer. The study of poorly explored molecular processes, such as splicing, can provide new tools in this regard. Alternative splicing of pre-RNA allows the generation of multiple RNA variants from a single gene and thereby contributes to fundamental biological processes by finely tuning gene expression. However, alterations in alternative splicing are linked to many diseases, and particularly to cancer, where it can contribute to tumor initiation, progression, metastasis and drug resistance. Splicing defects are increasingly being associated with PDAC, including both mutations or dysregulation of components of the splicing machinery and associated factors, and altered expression of specific relevant gene variants. Such disruptions can be a key element enhancing pancreatic tumor progression or metastasis, while they can also provide suitable tools to identify potential candidate biomarkers and discover new actionable targets. In this review, we aimed to summarize the current information about dysregulation of splicing-related elements and aberrant splicing isoforms in PDAC, and to describe their relationship with the development, progression and/or aggressiveness of this dismal cancer, as well as their potential as therapeutic tools and targets., This work has been supported by Spanish Ministry of Economy [MINECO; BFU2016-80360-R (to JPC)] and Ministry of Science and Innovation [MICINN; PID2019-105201RB-I00 (to JPC), PID2019-105564RB-I00 (to RML)]. Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF, “Investing in your future”) [FIS DTS Grant DTS20/00050 (to RML)); Postdoctoral Grant Sara Borrell CD19/00255 (to AIC); Predoctoral contract FI17/00282 (to EAP)]. Spanish Ministry of Universities [FPU20/03958 (to VGV); FPU18/02275 (to RBE); postdoctoral contract under the program María Zambrano funded by the European Union Next Generation-EU (to SPA)]. Asociación Cáncer de Páncreas and AESPANC 2022 (to JPC); Boehringer Ingelheim Fonds travel grant (EAP). Junta de Andalucía (BIO-0139). GETNE2016 and GETNE2019 Research grants (to JPC); and CIBERobn. Part of this work was supported by COST (European Cooperation in Science and Technology – www.cost.eu) through the COST Action TRANSPAN (CA21116)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features

  • Flores-Martínez, Alvaro
  • Venegas Moreno, Eva
  • Dios Fuentes, Elena
  • Remón-Ruiz, Pablo
  • Gros Herguido, Noelia
  • Vázquez-Borrego, Mari C.
  • Madrazo Atutxa, Ainara
  • Japón, Miguel A.
  • Kaen, Ariel
  • Cárdenas Ruiz-Valdepeñas, Eugenio
  • Roldán, Florinda
  • Castaño, Justo P.
  • Luque, Raúl M.
  • Cano González, David A.
  • Soto-Moreno, Alfonso
The primary treatment for non-functioning pituitary tumors (NFPTs) is surgery, but it is often unsuccessful. Previous studies have reported that NFPTs express receptors for somatostatin (SST1-5) and dopamine (DRDs) providing a rationale for the use of dopamine agonists and somatostatin analogues. Here, we systematically assessed SST1-5 and DRDs expression by real-time quantitative PCR (RT-qPCR) in a large group of patients with NFPTs (n = 113) and analyzed their potential association with clinical and molecular aggressiveness features. SST1-5 expression was also evaluated by immunohistochemistry. SST3 was the predominant SST subtype detected, followed by SST2, SST5, and SST1. DRD2 was the dominant DRD subtype, followed by DRD4, DRD5, and DRD1. A substantial proportion of NFPTs displayed marked expression of SST2 and SST5. No major association between SSTs and DRDs expression and clinical and molecular aggressiveness features was observed in NFPTs., This work was supported by grants from the ISCIII-Subdirección General de Evaluación y Fomento de la Investigación co-funded with Fondos FEDER (PI16/00175 to A.S.-M. and D.A.C; PI16/00264 to R.M.L.), the Sistema Andaluz de Salud (A-0006-2017 and A-0055-2018 to A.S.-M, C-0015-2014 and RC-0006-2018 to D.A.C.), Ministerio de Ciencia, Innovación (BFU2016-80360-R to J.P.C.; PID2019-105564RB-I00 to R.M.L.) and Junta de Andalucía (BIO-0139 to J.P.C. and R.M.L.), and CIBERobn. CIBER is an initiative of Instituto de Salud Carlos III, Ministerio de Sanidad, Servicios Sociales e Igualdad, Spain. Part of the analyses included in this study was carried out within the REMAH (‘Spanish molecular registry of pituitary adenomas’) project, supported by Novartis Oncology as well as by the Andalusian and Spanish Societies of Endocrinology and Nutrition (SAEDYN and SEEN, respectively)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Metabolic Fingerprint of Acromegaly and Its Potential Usefulness in Clinical Practice

  • Biagetti, Betina|||0000-0002-8837-4343
  • Herance, José Raul|||0000-0001-7178-3290
  • Ferrer Costa, Roser|||0000-0002-8925-3172
  • Aulinas, Anna|||0000-0002-1205-7114
  • Palomino-Schätzlein, Martina
  • Mesa Manteca, Jordi|||0000-0001-8616-605X
  • Castaño, Justo P.|||0000-0002-3145-7287
  • Luque, Raúl M.
  • Simó Canonge, Rafael|||0000-0003-0475-3096
Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) levels are the main targets for monitoring acromegaly activity, but they are not in close relationship with the clinical course of the disease and the associated comorbidities. The present study was aimed at identifying metabolites that could be used as biomarkers for a better disease phenotyping. For this purpose, metabolic fingerprint using an untargeted metabolomic approach was examined in serum from 30 patients with acromegaly and 30 age-matched controls. Patients with acromegaly presented fewer branched-chain amino acids (BCAAs) compared to the control group (valine: 4.75 ± 0.87 vs. 5.20 ± 1.06 arbitrary units (AUs), p < 0.05; isoleucine: 2.54 ± 0.41 vs. 2.80 ± 0.51 AUs; p < 0.05). BCAAs were also lower in patients with active disease compared to patients with normal levels of IGF-1 with or without medical treatment. GH, but not IGF-1, serum levels were inversely correlated with both valine and isoleucine. These findings indicate that low levels of BCAAs represent the main metabolic fingerprint of acromegaly and that GH, rather than IGF-1, might be the primary mediator. In addition, our results suggest that the assessment of BCAAs could help to identify active disease and to monitor the response to therapeutic strategies.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Cytokines and lymphoid populations as potential biomarkers in locally and borderline pancreatic adenocarcinoma

  • González Borja, Iranzu
  • Viúdez, Antonio
  • Alors-Pérez, Emilia
  • Goñi Irigoyen, Saioa
  • Amat Villegas, Irene
  • Ghanem, Ismael
  • Pazo-Cid, Roberto
  • Feliu, Jaime
  • Alonso, Laura
  • López López, Carlos
  • Arrazubi, Virginia
  • Gallego, Javier
  • Pérez Sanz, Jairo
  • Hernández García, Irene
  • Vera García, Ruth
  • Castaño, Justo P.
  • Fernández Irigoyen, Joaquín
Despite its relative low incidence, PDAC is one of the most aggressive and lethal types of cancer, being currently the seventh leading cause of cancer death worldwide, with a 5-year survival rate of 10.8%. Taking into consideration the necessity to improve the prognosis of these patients, this research has been focused on the discovery of new biomarkers. For this purpose, patients with BL and resectable disease were recruited. Serum cytokines and growth factors were monitored at different time points using protein arrays. Immune cell populations were determined by flow cytometry in peripheral blood as well as by immunohistochemistry (IHC) in tumor tissues. Several cytokines were found to be differentially expressed between the study subgroups. In the BL disease setting, two different scores were proven to be independent prognostic factors for progression-free survival (PFS) (based on IL-10, MDC, MIF, and eotaxin-3) and OS (based on eotaxin-3, NT-3, FGF-9, and IP10). In the same context, CA19-9 was found to play a role as independent prognostic factor for OS. Eotaxin-3 and MDC cytokines for PFS, and eotaxin-3, NT-3, and CKβ8-1 for OS, were shown to be predictive biomarkers for nab-paclitaxel and gemcitabine regimen. Similarly, oncostatin, BDNF, and IP10 cytokines were proven to act as predictive biomarkers regarding PFS, for FOLFIRINOX regimen. In the resectable cohort, RANTES, TIMP-1, FGF-4, and IL-10 individually differentiated patients according to their cancer-associated survival. Regarding immune cell populations, baseline high levels of circulating B lymphocytes were related to a significantly longer OS, while these levels significantly decreased as progression occurred. Similarly, baseline high levels of helper lymphocytes (CD4+), low levels of cytotoxic lymphocytes (CD8+), and a high CD4/CD8 ratio, were related to a significantly longer PFS. Finally, high levels of CD4+ and CD8+ intratumoural infiltration was associated with significantly longer PFS. In conclusion, in this study we were able to identify several prognostic and predictive biomarker candidates in patients diagnosed of resectable or BL PDAC., This work was funded by grants from the Department of Health from the Government of Navarra (Ref. 008-2018), REFBIO II Pyrenees Biomedical Network from Programa INTERREG V-A España-Francia-Andorra (Ref. BMK_PANC) and Sociedad Española de Oncología Médica (SEOM) to A.V. I.G.B was supported by a predoctoral fellowship from the Department of Economic Development Government of Navarre Ayudas para la contratación de doctorandos y doctorandas por empresas y organismos de investigación y difusión de conocimientos: doctorados industriales 2018–2020. Intensification Programme Navarrabiomed 2017–2021 Obra Social La Caixa Fundación Caja Navarra. Work by JPC received funds from Spanish Ministry of Economy (MINECO; BFU2016–80360-R) and Ministry of Science and Innovation (MICINN; PID2019-105201RB-I00), Junta de Andalucía (BIO- 0139), Universidad de Córdoba-FEDER (UCO-202099901918904), GETNE2019 Research grant; and CIBERobn Fisiopatología de la Obesidad y Nutrición (CIBER is an initiative of Instituto de Salud Carlos III, co-funded by European Union: ERDF/ESF, “Investing in your future”). EAP was funded by a Predoctoral contract FI17/00282 Instituto de Salud Carlos III.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Deciphering CHFR role in pancreatic ductal adenocarcinoma

  • González Borja, Iranzu
  • Alors-Pérez, Emilia
  • Amat Villegas, Irene
  • Alonso, Laura
  • Viyuela-García, Cristina
  • Goñi Irigoyen, Saioa
  • Reyes, José C.
  • Ceballos-Chávez, María
  • Hernández García, Irene
  • Sánchez-Frías, Marina E.
  • Santamaría Martínez, Enrique
  • Razquin, Socorro
  • Arjona Sánchez, Álvaro
  • Arrazubi, Virginia
  • Pérez Sanz, Jairo
  • Vera García, Ruth
  • Fernández Irigoyen, Joaquín
  • Castaño, Justo P.
  • Viúdez, Antonio
Checkpoint with forkhead-associated and ring finger domains (CHFR) has been proposed as a predictive and prognosis biomarker for different tumor types, but its role in pancreatic ductal adenocarcinoma (PDAC) remains unknown. The aim of this study was two-pronged: to review the role of CHFR in PDAC and evaluating CHFR as a potential predictive biomarker in this disease. For this purpose, we first explored the CHFR messenger (m)RNA expression and promoter methylation through the TCGA database. Secondly, the CHFR expression and promoter methylation were prospectively evaluated in a cohort of patients diagnosed with borderline (n = 19) or resectable (n = 16) PDAC by immunohistochemistry (IHC), methylation specific-PCR (MSP), and pyrosequencing. The results from the TCGA database showed significant differences in terms of progression-free survival (PFS) and overall survival (OS) based on the CHFR mRNA expression, which was likely independent from the promoter methylation. Importantly, our results showed that in primarily resected patients and also the entire cohort, a higher CHFR expression as indicated by the higher IHC staining intensity might identify patients with longer disease-free survival (DFS) and OS, respectively. Similarly, in the same cohorts, patients with lower methylation levels by pyrosequencing showed significantly longer OS than patients without this pattern. Both, the CHFR expression intensity and its promoter methylation were established as independent prognostic factors for PFS and OS in the entire cohort. In contrast, no significant differences were found between different methylation patterns for CHFR and the response to taxane-based neoadjuvant treatment. These results suggest the potential role of the higher expression of CHFR and the methylation pattern of its promoter as potential prognostic biomarkers in PDAC, thus warranting further comprehensive studies to extend and confirm our preliminary findings., This work was funded by grants from the Department of Health from the Government of Navarra (Ref. 008-2018), REFBIO II Pyrenees Biomedical Network from Programa INTERREG V-A España-Francia-Andorra (Ref. BMK_PANC) and Sociedad Española de Oncología Médica (SEOM) to AV. IG-B was supported by a predoctoral fellowship from the Department of Economic Development Government of Navarre Ayudas para la contratación de doctorandos y doctorandas por empresas y organismos de investigación y difusión de conocimientos: doctorados industriales 2018–2020. Intensification Programme Navarrabiomed 2017-2021 Obra Social La Caixa Fundación Caja Navarra. This work has also been supported by the Spanish Ministry of Economy [MINECO; BFU2016-80360-R (to JC)] and the Ministry of Science and Innovation [MICINN; PID2019-105201RB-I00 (to JC)]. Instituto de Salud Carlos III, co-funded by European Union (ERDF/ESF, Investing in your future) [Predoctoral contract FI17/00282 (to EA-P)]. Junta de Andalucía (BIO-0139); GETNE2016 and GETNE2019 Research grants (to JC); and CIBERobn.